ABBVIE INC. vs. Spyre Therapeutics, Inc. Common Stock
ABBVIE INC. and Spyre Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABBV | SYRE | |
|---|---|---|
| Market Cap | $464.58 billion | $8.25 billion |
| Revenue (TTM) | $64.39 billion | — |
| Net Income (TTM) | $6.32 billion | — |
ABBV leads on 1 of 1 size & scale factors.
Valuation
| ABBV | SYRE | |
|---|---|---|
| P/E Ratio | 73.09 | — |
| Price / Book | -78.90 | — |
| Price / Sales | 7.22 | — |
ABBV and SYRE split the valuation factors evenly.
Profitability
| ABBV | SYRE | |
|---|---|---|
| Net Margin | 9.81% | — |
| Return on Equity | -107.29% | — |
ABBV and SYRE split the profitability factors evenly.
Dividend
| ABBV | SYRE | |
|---|---|---|
| Dividend Yield | 2.67% | — |
| Payout Ratio | 195.48 | — |
ABBV and SYRE split the dividend factors evenly.
Risk & Sentiment
| ABBV | SYRE | |
|---|---|---|
| Short Interest | 0.85% | 0.23% |
SYRE leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, SYRE overview, SYRE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.